CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukaemia – a case report

CPX-351 is a promising new therapeutic option for patients with treatment related (tAML) or secondary acute myeloid leukemia (sAML). It exceeded classic 7+3 therapy in overall survival (OS) and complete remission rates (CR) while providing a similar risk profile. Until now, this sub-group of AML patients had a worse overall